A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, remains a devastating disease with a dismal prognosis and limited survival rates. Despite various drug treatments and regimens showing promise in managing the disease, the clinical outcomes have not significantly improved. Immunothera...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmacology 2024-04, Vol.969, p.176451-176451, Article 176451 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 176451 |
|---|---|
| container_issue | |
| container_start_page | 176451 |
| container_title | European journal of pharmacology |
| container_volume | 969 |
| creator | Balar, Pankti C. Apostolopoulos, Vasso Chavda, Vivek P. |
| description | Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, remains a devastating disease with a dismal prognosis and limited survival rates. Despite various drug treatments and regimens showing promise in managing the disease, the clinical outcomes have not significantly improved. Immunotherapy however, has become a forefront area in pancreatic cancer treatment. This approach comprises a range of agents, including small molecule drugs, antibodies, combination therapies, and vaccines. In the last 5–8 years, there has been an upsurge of research into the use of monoclonal antibodies to block receptors on cancer or immune cells, revolutionising cancer treatment and management. Several targets have been identified and studied, with the most encouraging noted in relation to checkpoint markers, namely, antibodies targeting anti-programmed cell death 1 (PD-1) and its receptor PD-L1. Herein, we present the clinical developments in immunotherapy in the last 5 years especially those which have been tested in humans against pancreatic cancer. |
| doi_str_mv | 10.1016/j.ejphar.2024.176451 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2932437669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299924001390</els_id><sourcerecordid>2932437669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-e47a969250c4098b2a67e3b43feedfa0d0871b8833be44a3a9dc61ed23e8b1783</originalsourceid><addsrcrecordid>eNp9kEtLxDAQgIMouj7-gUiOXrrmtW3iQZDFF6x40ZsQ0nSqWdqmJu2K_94sVY-eZga-eX0InVIyp4TmF-s5rPt3E-aMMDGnRS4WdAfNqCxURgrKdtGMECoyppQ6QIcxrgkhC8UW--iAS0HkQskZer3GHXxiCAb7Gru2HTvAw3uqexgHZyOufcC96WwAk2psUwrhEj_6ztvGd6bBphtc6SsHMYEb171tB-BP83WM9mrTRDj5iUfo5fbmeXmfrZ7uHpbXq8zynA0ZiMKoPF1GrCBKlszkBfBS8Bqgqg2piCxoKSXnJQhhuFGVzSlUjIMsaSH5ETqf5vbBf4wQB926aKFpTAd-jJopzgQv8lwlVEyoDT7GALXug2tN-NKU6K1XvdaTV731qievqe3sZ8NYtlD9Nf2KTMDVBED6c-Mg6GgdJFWVC2AHXXn3_4ZvmR6LgA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2932437669</pqid></control><display><type>article</type><title>A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Balar, Pankti C. ; Apostolopoulos, Vasso ; Chavda, Vivek P.</creator><creatorcontrib>Balar, Pankti C. ; Apostolopoulos, Vasso ; Chavda, Vivek P.</creatorcontrib><description>Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, remains a devastating disease with a dismal prognosis and limited survival rates. Despite various drug treatments and regimens showing promise in managing the disease, the clinical outcomes have not significantly improved. Immunotherapy however, has become a forefront area in pancreatic cancer treatment. This approach comprises a range of agents, including small molecule drugs, antibodies, combination therapies, and vaccines. In the last 5–8 years, there has been an upsurge of research into the use of monoclonal antibodies to block receptors on cancer or immune cells, revolutionising cancer treatment and management. Several targets have been identified and studied, with the most encouraging noted in relation to checkpoint markers, namely, antibodies targeting anti-programmed cell death 1 (PD-1) and its receptor PD-L1. Herein, we present the clinical developments in immunotherapy in the last 5 years especially those which have been tested in humans against pancreatic cancer.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2024.176451</identifier><identifier>PMID: 38408598</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Carcinoma, Pancreatic Ductal - drug therapy ; Combined Modality Therapy ; Gemcitabine ; Humans ; Immunotherapy ; mAb ; Monoclonal antibody treatment ; Nivolumab ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - metabolism ; PD-1 ; PDAC ; SBRT ; Vaccine</subject><ispartof>European journal of pharmacology, 2024-04, Vol.969, p.176451-176451, Article 176451</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-e47a969250c4098b2a67e3b43feedfa0d0871b8833be44a3a9dc61ed23e8b1783</citedby><cites>FETCH-LOGICAL-c362t-e47a969250c4098b2a67e3b43feedfa0d0871b8833be44a3a9dc61ed23e8b1783</cites><orcidid>0000-0002-7701-8597</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2024.176451$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38408598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Balar, Pankti C.</creatorcontrib><creatorcontrib>Apostolopoulos, Vasso</creatorcontrib><creatorcontrib>Chavda, Vivek P.</creatorcontrib><title>A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, remains a devastating disease with a dismal prognosis and limited survival rates. Despite various drug treatments and regimens showing promise in managing the disease, the clinical outcomes have not significantly improved. Immunotherapy however, has become a forefront area in pancreatic cancer treatment. This approach comprises a range of agents, including small molecule drugs, antibodies, combination therapies, and vaccines. In the last 5–8 years, there has been an upsurge of research into the use of monoclonal antibodies to block receptors on cancer or immune cells, revolutionising cancer treatment and management. Several targets have been identified and studied, with the most encouraging noted in relation to checkpoint markers, namely, antibodies targeting anti-programmed cell death 1 (PD-1) and its receptor PD-L1. Herein, we present the clinical developments in immunotherapy in the last 5 years especially those which have been tested in humans against pancreatic cancer.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Carcinoma, Pancreatic Ductal - drug therapy</subject><subject>Combined Modality Therapy</subject><subject>Gemcitabine</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>mAb</subject><subject>Monoclonal antibody treatment</subject><subject>Nivolumab</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>PD-1</subject><subject>PDAC</subject><subject>SBRT</subject><subject>Vaccine</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxDAQgIMouj7-gUiOXrrmtW3iQZDFF6x40ZsQ0nSqWdqmJu2K_94sVY-eZga-eX0InVIyp4TmF-s5rPt3E-aMMDGnRS4WdAfNqCxURgrKdtGMECoyppQ6QIcxrgkhC8UW--iAS0HkQskZer3GHXxiCAb7Gru2HTvAw3uqexgHZyOufcC96WwAk2psUwrhEj_6ztvGd6bBphtc6SsHMYEb171tB-BP83WM9mrTRDj5iUfo5fbmeXmfrZ7uHpbXq8zynA0ZiMKoPF1GrCBKlszkBfBS8Bqgqg2piCxoKSXnJQhhuFGVzSlUjIMsaSH5ETqf5vbBf4wQB926aKFpTAd-jJopzgQv8lwlVEyoDT7GALXug2tN-NKU6K1XvdaTV731qievqe3sZ8NYtlD9Nf2KTMDVBED6c-Mg6GgdJFWVC2AHXXn3_4ZvmR6LgA</recordid><startdate>20240415</startdate><enddate>20240415</enddate><creator>Balar, Pankti C.</creator><creator>Apostolopoulos, Vasso</creator><creator>Chavda, Vivek P.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7701-8597</orcidid></search><sort><creationdate>20240415</creationdate><title>A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way</title><author>Balar, Pankti C. ; Apostolopoulos, Vasso ; Chavda, Vivek P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-e47a969250c4098b2a67e3b43feedfa0d0871b8833be44a3a9dc61ed23e8b1783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Carcinoma, Pancreatic Ductal - drug therapy</topic><topic>Combined Modality Therapy</topic><topic>Gemcitabine</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>mAb</topic><topic>Monoclonal antibody treatment</topic><topic>Nivolumab</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>PD-1</topic><topic>PDAC</topic><topic>SBRT</topic><topic>Vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Balar, Pankti C.</creatorcontrib><creatorcontrib>Apostolopoulos, Vasso</creatorcontrib><creatorcontrib>Chavda, Vivek P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Balar, Pankti C.</au><au>Apostolopoulos, Vasso</au><au>Chavda, Vivek P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2024-04-15</date><risdate>2024</risdate><volume>969</volume><spage>176451</spage><epage>176451</epage><pages>176451-176451</pages><artnum>176451</artnum><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, remains a devastating disease with a dismal prognosis and limited survival rates. Despite various drug treatments and regimens showing promise in managing the disease, the clinical outcomes have not significantly improved. Immunotherapy however, has become a forefront area in pancreatic cancer treatment. This approach comprises a range of agents, including small molecule drugs, antibodies, combination therapies, and vaccines. In the last 5–8 years, there has been an upsurge of research into the use of monoclonal antibodies to block receptors on cancer or immune cells, revolutionising cancer treatment and management. Several targets have been identified and studied, with the most encouraging noted in relation to checkpoint markers, namely, antibodies targeting anti-programmed cell death 1 (PD-1) and its receptor PD-L1. Herein, we present the clinical developments in immunotherapy in the last 5 years especially those which have been tested in humans against pancreatic cancer.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38408598</pmid><doi>10.1016/j.ejphar.2024.176451</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7701-8597</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2999 |
| ispartof | European journal of pharmacology, 2024-04, Vol.969, p.176451-176451, Article 176451 |
| issn | 0014-2999 1879-0712 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2932437669 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies, Monoclonal - therapeutic use Carcinoma, Pancreatic Ductal - drug therapy Combined Modality Therapy Gemcitabine Humans Immunotherapy mAb Monoclonal antibody treatment Nivolumab Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism PD-1 PDAC SBRT Vaccine |
| title | A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T15%3A59%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20era%20of%20immune%20therapeutics%20for%20pancreatic%20cancer:%20Monoclonal%20antibodies%20paving%20the%20way&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Balar,%20Pankti%20C.&rft.date=2024-04-15&rft.volume=969&rft.spage=176451&rft.epage=176451&rft.pages=176451-176451&rft.artnum=176451&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2024.176451&rft_dat=%3Cproquest_cross%3E2932437669%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2932437669&rft_id=info:pmid/38408598&rft_els_id=S0014299924001390&rfr_iscdi=true |